Baseline Cytomegalovirus Immunoglobulin G Levels Predict Reactivation in Patients With Multiple Myeloma Receiving Elranatamab
Baseline CMV IgG titers may help guide risk-adapted monitoring and prevention strategies during elranatamab therapy.
Authors
- Taku Kikuchi (ORCID: https://orcid.org/0000-0002-3210-7756)
- Kota Sato (ORCID: https://orcid.org/0000-0001-9239-6003)
- So SUGITA
- Osamu Hosoya
- Chiaki Matsumoto (ORCID: https://orcid.org/0000-0002-6505-593X)
- Miyu Watanabe
- Tomomi Takei (ORCID: https://orcid.org/0000-0002-0422-0030)
- Tadao Ishida
- Kodai Kunisada
- Moe Nomura‐Yogo
- Yu Abe (ORCID: https://orcid.org/0000-0003-2622-3141)
- Nobuhiro Tsukada
- Mizuki Ogura
- Ukyo Kondo
Institutions
- Japanese Red Cross Medical Center (JP)
Publication Details
- Journal
- eJHaem
- Published
- 2025-11-28
- DOI
- https://doi.org/10.1002/jha2.70189
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00